207 related articles for article (PubMed ID: 30962502)
1. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.
Lübking A; Dreimane A; Sandin F; Isaksson C; Märkevärn B; Brune M; Ljungman P; Lenhoff S; Stenke L; Höglund M; Richter J; Olsson-Strömberg U
Bone Marrow Transplant; 2019 Nov; 54(11):1764-1774. PubMed ID: 30962502
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.
Özen M; Üstün C; Öztürk B; Topçuoğlu P; Arat M; Gündüz M; Atilla E; Bolat G; Arslan Ö; Demirer T; Akan H; İlhan O; Beksaç M; Gürman G; Özcan M
Turk J Haematol; 2017 Mar; 34(1):16-26. PubMed ID: 27094579
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
Kondo T; Nagamura-Inoue T; Tojo A; Nagamura F; Uchida N; Nakamae H; Fukuda T; Mori T; Yano S; Kurokawa M; Ueno H; Kanamori H; Hashimoto H; Onizuka M; Takanashi M; Ichinohe T; Atsuta Y; Ohashi K
Am J Hematol; 2017 Sep; 92(9):902-908. PubMed ID: 28543934
[TBL] [Abstract][Full Text] [Related]
4. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era.
Shimada H; Tanizawa A; Kondo T; Nagamura-Inoue T; Yasui M; Tojo A; Muramatsu H; Eto T; Doki N; Tanaka M; Sato M; Noguchi M; Uchida N; Takahashi Y; Sakata N; Ichinohe T; Hashii Y; Kato K; Atsuta Y; Ohashi K;
Transplant Cell Ther; 2022 Jul; 28(7):376-389. PubMed ID: 35447373
[TBL] [Abstract][Full Text] [Related]
6. [Management of advanced-phase chronic myeloid leukemia].
Kitanaka A
Rinsho Ketsueki; 2016; 57(10):1962-1971. PubMed ID: 27725594
[TBL] [Abstract][Full Text] [Related]
7. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of children with chronic myeloid leukemia: A population-based cohort study.
Egan G; Athale U; Johnston D; Pole JD; Silva M; Zorzi A; Alexander S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28491. PubMed ID: 32589368
[TBL] [Abstract][Full Text] [Related]
9. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
10. Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up.
Tavakoli S; Khalaj F; Kasaeian A; Mousavi SA; Mousavian AH; Arabi F; Rad S; Rostami S; Barkhordar M; Biglari M; Mardani-Fard HA; Alemi H; Khavandgar N; Kamranzadeh Fumani H; Janbabai G; Mousavi SA; Ghavamzadeh A; Vaezi M
Cell Transplant; 2023; 32():9636897231163212. PubMed ID: 37013251
[TBL] [Abstract][Full Text] [Related]
11. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
[TBL] [Abstract][Full Text] [Related]
12. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu Y; Murata M; Kondo T; Minami Y; Tachibana T; Doki N; Uchida N; Ozawa Y; Yano S; Fukuda T; Kato J; Ara T; Eto T; Ishikawa J; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Nagamura-Inoue T;
Hematol Oncol; 2022 Aug; 40(3):442-456. PubMed ID: 35394658
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.
Jiang H; Xu LP; Liu DH; Liu KY; Chen SS; Jiang B; Jiang Q; Chen H; Chen YH; Han W; Zhang XH; Wang Y; Wang JZ; Wang FR; Qin YZ; Lai YY; Huang XJ
Bone Marrow Transplant; 2014 Sep; 49(9):1146-54. PubMed ID: 25046218
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
Chalandon Y; Sbianchi G; Gras L; Koster L; Apperley J; Byrne J; Salmenniemi U; Sengeloev H; Aljurf M; Helbig G; Kinsella F; Choi G; Reményi P; Snowden JA; Robin M; Lenhoff S; Mielke S; Passweg J; Broers AEC; Kröger N; Yegin ZA; Tan SM; Hayden PJ; McLornan DP; Yakoub-Agha I;
Am J Hematol; 2023 Jan; 98(1):112-121. PubMed ID: 36266607
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Patients With Chronic Phase CML Resistant or Intolerant to Tyrosine Kinase Inhibitors.
Yassine F; Reljic T; Moustafa MA; Iqbal M; Murthy HS; Kumar A; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Mar; 15(1):36-43. PubMed ID: 33789163
[TBL] [Abstract][Full Text] [Related]
16. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
Poiré X; Artz A; Larson RA; Kline J; Odenike O; Rich E; Godley L; Stock W; van Besien K
Leuk Lymphoma; 2009 Jan; 50(1):85-91. PubMed ID: 19142796
[TBL] [Abstract][Full Text] [Related]
20. Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era.
Savoie ML; Bence-Bruckler I; Huebsch LB; Lalancette M; Hillis C; Walker I; Lipton JH; Forrest DL; Kim DDH
Leuk Res; 2018 Oct; 73():67-75. PubMed ID: 30227318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
